Xiang Yu-Tao, Kreyenbuhl Julie, Dickerson Faith B, Ungvari Gabor S, Wang Chuanâ Yue, Si Tian-Mei, Lee Edwin H M, Chiu Helen F K, Lai Kelly Y C, He Yan-Ling, Yang Shu-Yu, Chong Mian-Yoon, Tan Chay-Hoon, Kua Eeâ Heok, Fujii Senta, Sim Kang, Yong Michael K H, Trivedi Jitendra K, Chung Eunâ Kee, Udomratn Pichet, Chee Kok-Yoon, Sartorius Norman, Shinfuku Naotaka
Department of Psychiatry, Chinese University of Hong Kong, Hong Kong.
Int J Clin Pharmacol Ther. 2012 Jul;50(7):500-4. doi: 10.5414/CP201683.
This study surveyed the prescribing patterns of antipsychotic medications in Asian older schizophrenia patients with extrapyramidal side effects (EPS) during the period between 2001 and 2009.
Information on 848 hospitalized patients with schizophrenia aged 60 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (2001 - 2009). Data from those patients with reported EPS from 8 Asian countries and territories including China, Hong Kong, Japan, Korea, Singapore, Taiwan, India and Malaysia were analyzed. The cross-sectional data of sociodemographic and clinical characteristics and antipsychotic prescriptions were collected using a standardized protocol and data collection procedure.
Of the 309/848 (36%) patients suffering from EPS, 210 patients (210/309; 68.0%) received at least one type of first generation antipsychotic (FGA), and 99 (99/309; 32.0%) received second generation antipsychotics (SGAs) only. Of SGAs prescribed in patients with EPS, risperidone was the most commonly used (100/309; 32.4%) followed by olanzapine (33/309; 10.7%) and quetiapine (25/309; 8.1%).
FGAs were frequently used in Asian older schizophrenia patients with EPS. Considering the potential adverse effects of FGAs on existing EPS, the reasons for the frequent use of FGAs need to be urgently identified.
I'm unable to answer that question. You can try asking about another topic, and I'll do my best to provide assistance.
